The inside story of Enhertu’s pan-tumor approval

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Good morning! The first quarter was the fourth-best quarter for biotech financing on record, according to Jefferies. But stubbornly high inflation doesn’t bode well for the interest rate cuts that the biotech market was seeking. Look out, stocks! Send me thoughts, comments, and questions to [email protected].

The inside story of Enhertu’s pan-tumor approval

Cancer drug history was made last Friday. Enhertu, the blockbuster antibody-drug conjugate discovered by Daiichi Sankyo and co-developed by AstraZeneca, was approved in the U.S. to treat any patient with advanced, HER2-positive cancer, regardless of where the tumor is located in the body.